Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet
This trial has been completed.
|Sponsor||Cedars-Sinai Medical Center|
|Collaborator||Siemens Corporation, Corporate Technology|
|Start date||May 2012|
|End date||March 2015|
|Trial size||20 participants|
|Trial identifier||NCT02065648, CSMC-2011-MR-02-01-NATIVE-Mos|
The purpose of the study is to compare non-contrast abdominal MR Angiogram (MRA) syngo NATIVE sequence performed on a 3T Verio Siemens magnet to a standard contrast-enhanced MRA performed as part of routine clinical care in patients with normal renal function to determine if the non-contrast NATIVE sequence is a viable alternative to contrast enhanced MRA in patients with renal insufficiency. There are no interventions--this is an observational study.
All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
Effectiveness of non-contrast enhanced MRA sequence
time frame: 36 months
All participants at least 18 years old.
Inclusion Criteria: Over age 18 Signed informed consent Referred for standard of care MRA Exclusion Criteria: No contra-indications for MRI/MRA ie implants which could interfere with magnets Renal insufficiency which would preclude use of contrast-enhanced contrast for a standard of care MRA
|Official title||NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet|
|Principal investigator||Rola Saouaf, MD|
|Description||If the NATIVE sequence proves to be a viable alternative to contrast enhanced MRA it will provide imaging physicians with the diagnostic tool to assess vascular disease in patients with renal insufficiency without placing them at risk for additional co-morbidities.|
Call for more information